The Latest York Times (NYT) made a claim that Elon Musk CEO had taken a considerable amount of drugs, including drugs throughout the presidential election campaign last 12 months. Musk accused him of being a “false newspaper newspaper.”
NYT reported on Wednesday that the CEO of Musk cited a considerable amount of drugs, including ecstasy and mushrooms, while the CEO of Musk was supporting President Donald Trump’s election campaign last 12 months.
Based on those that know the Musk CEO, he carried a box of 20 pills, including Awakening, Intral, and the use of medication has exceeded on a regular basis levels. Specifically, it was informed that excessive ketamine was taking problems with the bladder.
After joining the White House, it’s unclear whether he continued to take the drug. Nevertheless, he continued unstable behavior, blaming the members of the cupboard and causing a lot of water to the Nazi salute on the event.
He also introduced that he had put his hands on the drug. He said in social media, “I felt great happiness, terrible downturn, and constant stress.” He also strongly criticized traditional treatment and antidepressants.
The Wall Street Journal reported last 12 months that he had an influence of using drugs for hallucinations. Some members of Tesla have been concerned concerning the use of medication, including Sleep Sleep, an Embien.
He also said he was taking a small amount of ketamine every two weeks to treat negative moods when he was accused of popping up throughout the interview last March.
But those that attended the people around me or party often said ketamine, sometimes every day, and mixed with other drugs. The boundary between medical and hallucinations was ambiguous. It was also said that he took ecstasy and hallucinations at a non-public meeting.
After the news was announced, Musk CEO was asked about drug problems. He said, “Is NYT a newspaper that received a Pulitzer Prize for false Russian gates?”
Within the evening, President Trump didn’t know that the Musk CEO was popping up usually.
By Dae -jun Lim, reporter ydj@aitimes.com
